Signal transduction targets in androgen-independent prostate cancer

Cancer and Metastasis Reviews

Volumn 20, Issue 3-4, 2001, Pages 351-362

  Zhou, Jian ^a   Scholes, Jessica ^a   Hsieh, Jer Tsong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Androgen independent prostate cancer; Growth factor; Prostate cancer; Signal transduction; Tumor suppressor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANDROGEN; ANDROSTANOLONE; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; MALE; MALIGNANT TRANSFORMATION; METASTASIS; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0035740349     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015504015302     Document Type: Review

References (122)

1. Interaction of drugs, hormones and nutrition in the causes of cancer
2. Chinesische eunuchen
3. Mortality and survival: Comparison of eunuchs with intact men and women in a mentally retarded population
4. The development of prostatic adenocarcinoma in NB rats following prolonged sex hormone administration
5. Production of autochtoneous prostate cancer in Lobound-Wistar rats by treatment with N-nitroso-N-methylurea and testosterone
6. Studies on prostatic cancer I. The effect of castration of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate
7. The effects of androgen withdrawal on the stem cell composition of Shionogi carcinoma
8. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model
9. Etiology and disease process of benign prostatic hyperplasia
10. Clinical and experimental studies of benign prostatic hyperplasia
11. Response of glandular versus basal rat ventral prostate
12. Direct mitogenic effects of insulin, epidermal growth factor and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free primary cell culture
13. In vitro studies of human prostate epithelial cells
14. Urogastrone-epidermal growth factor concentration in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy
15. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
16. Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissue
17. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma
18. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-α in the progression of prostatic neoplasms
19. Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line
20. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α
21. Secretion of epidermal growth factor and related polypeptides by the Du 145 human prostate cell line
22. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines
23. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy
24. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer
25. Alternative splicing of fibroblast growth factor receptors in human prostate cancer
26. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
27. Basic fibroblast growth factor in human prostate cancer cells
28. Progression of androgen-sensitive mouse tumor (Shionogi cancinoma 115) to androgen-insensitive tumor after long-term removal of testosterone
29. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death
30. NGF-β, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-145, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-β
31. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate
32. Characterization of nerve growth factor precursor protein expression by human prostate stromal cells: A role in selective neurotrophin stimulation of prostate epithelial cell growth
33. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate
34. SH2/SH 3 signaling proteins
35. The MAPK siganling cascade
36. G protein-coupled receptors and signaling pathways regulating growth responses
37. The p21-Ras signal transduction pathway and growth regulation in human high-grade glioma
38. Ras genes
39. Identification and quantification of a carcinogen-induced molecular initiation event in cell trans formation
40. Ras oncogenes in human cancer: Review
41. Expression of ras oncogene p21 in prostate cancer
42. Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers
43. Ras gene mutation in human prostate cancer
44. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas
45. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells
46. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells
47. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility
48. Activated ras alleles in human carcinoma of the prostate are rare
49. Infrequent RAS oncogene mutations in human prostate cancer
50. Genetic alterations in human prostate cancer: A review of current literature
51. Abrogation of c-Raf expression induces apoptosis in tumor cells
52. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
53. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells
54. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase c-α
55. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
56. Transformation of mammalian cells by constitutively active MAP kinase kinase
57. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis
58. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma
59. Activation of mitogen-activated protein kinase associated with prostate cancer progression
60. Development of anticancer drugs targeting the MAP kinase pathway
61. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells
62. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line
63. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1
64. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors
65. Overexpression of cyclin D1 is rare in human prostate carcinoma
66. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone
67. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU 145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest
68. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway
69. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
70. Functional and molecular analyses of 10q deletions in human gliomas
71. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
72. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
73. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
74. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
75. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway
76. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
77. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells
78. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B
79. EGF receptor signaling enhances in vivo invasiveness of DU- 145 human prostate carcinoma cells
80. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE)
81. A role for phospholipase C-γ-mediated signaling in tumor cell invasion
82. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone
83. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion
84. Paxillin interactions
85. Mitogen-activated protein kinase pathway is involved in α6 integrin gene expression in androgen-independent prostate cancer cells: Role of proximal Sp1 consensus sequence
86. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line
87. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
88. The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity
89. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
90. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p 130Cas
91. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN
92. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells
93. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways
94. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
95. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
96. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
97. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
98. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells
99. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
100. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
101. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
102. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells
103. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells
104. Mouse disabled (mDab1): A Src binding protein implicated in neuronal development
105. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2
106. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer
107. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases
108. Disabled-2 inactivation is an early step in ovarian tumorigenicity
109. Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation
110. A genome-wide survey of RAS transformation targets
111. The gene encoding the mitogen-responsive phosphoprotein Dab2 is differentially regulated by GATA-6 and GATA-4 in the visceral endoderm
112. Differential expression of mouse Disabled 2 gene in retinoic acid-treated F9 embryonal carcinoma cells and early mouse embryos
113. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type
114. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3
115. Induction of disabled-2 gene during megakaryocyte differentiation of k562 cells
116. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer
117. A Novel RasGTPase activating protein that interacts with DOC-2/DAB2: A downstream effector leading to the suppression of prostate cancer
118. Differential regulation of the human DIP1/2 gene in normal and malignant prostatic epithelia: Cloning and characterization of the DIP1/2 gene
119. Identification of the tuberous sclerosis gene TSCI on chromosome 9q34
120. The adaptor molecule Disabled-2 links the transforming growth factor β receptors to the Smad pathway
121. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2